Related content

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease

By Müller T.   Erdmann C.   Muhlack S.   Bremen D.   Przuntek H.   Goetze O.   Woitalla D.  

Journal of Neural Transmission, Vol. 113, Iss. 10, 2006-10 ,pp. : 1441-1448

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

By Tolosa Eduardo   Hernández Basilio   Linazasoro Gurutz   López-Lozano Juan   Mir Pablo   Marey José   Kulisevsky Jaime  

Journal of Neural Transmission, Vol. 121, Iss. 4, 2014-04 ,pp. : 357-366

Springer Publishing Company

Access to resources Recommend Favorite

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease

By Cáceres-Redondo María   Carrillo Fátima   Lama María   Huertas-Fernández Ismael   Vargas-González Laura   Carballo Manuel   Mir Pablo  

Journal of Neurology, Vol. 261, Iss. 3, 2014-03 ,pp. : 561-569

Springer Publishing Company

Access to resources Recommend Favorite

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

By Onofrj M.   Thomas A.   Vingerhoets F.   Martin W.   Giménez-Roldán S.   Azulay J.-P.   Bernhard G.   Schmidt W.   Markabi S.  

Journal of Neural Transmission, Vol. 111, Iss. 8, 2004-08 ,pp. : 1053-1063

Springer Publishing Company

Access to resources Recommend Favorite

Acute levodopa administration reduces cortisol release in patients with Parkinson’s disease

By Müller T.   Welnic J.   Muhlack S.  

Journal of Neural Transmission, Vol. 114, Iss. 3, 2007-03 ,pp. : 347-350

Springer Publishing Company

Access to resources Recommend Favorite